Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

7.1K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
7.1K
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

30
Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
30
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

27
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH...
27
Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

23
Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence...
23
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

26
Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor,...
26
Goiter01:27

Goiter

32
Goiter refers to an abnormal enlargement of the thyroid gland that may appear as a diffuse goiter (uniform enlargement) or nodular (single or multiple nodules). Functionally, it is classified as nontoxic (normal/low hormone levels) or toxic (excess hormone production).PathophysiologyDiffuse thyroid enlargement typically results from prolonged stimulation by thyroid-stimulating hormone (TSH) or TSH-like agents, commonly seen in hypothyroidism or iodine deficiency. In contrast, in hyperthyroid...
32

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Universal screening to detect hypothyroidism in pregnant women.

European journal of endocrinology·2026
Same author

Subacute Thyroiditis in Denmark: A Nationwide Study of 1763 Cases.

Clinical endocrinology·2026
Same author

Indications of over- and undertreatment of hypothyroidism in primary care: a scoping review and evidence mapping.

Scandinavian journal of primary health care·2026
Same author

Maternal thyroid disease and the risk of excessive bleeding in pregnancy: a Danish nationwide cohort study.

Thyroid research·2026
Same author

Antithyroid drug treatment in pregnancy: A first report from the Danish PRETHYR multicenter study.

The Journal of clinical endocrinology and metabolism·2026
Same author

Selenium supplementation in individuals with newly diagnosed Graves' hyperthyroidism: a double-blind, multi-centre RCT.

European thyroid journal·2025
Same journal

Strengthening the metabolic alliance: exercise as an essential partner of obesity pharmacotherapy.

Nature reviews. Endocrinology·2026
Same journal

Reply to 'Post-thyrotoxicosis weight gain: time to stratify and treat?'

Nature reviews. Endocrinology·2026
Same journal

Post-thyrotoxicosis weight gain: time to stratify and treat?

Nature reviews. Endocrinology·2026
Same journal

Myostatin-targeting antibody protects lean mass during incretin-induced weight loss.

Nature reviews. Endocrinology·2026
Same journal

Macronutrient mixtures and interactions in health and disease.

Nature reviews. Endocrinology·2026
Same journal

Hepatic neurons and metabolically induced liver dysfunction.

Nature reviews. Endocrinology·2026
See all related articles

Related Experiment Video

Updated: Apr 30, 2026

Conversion of a Capture ELISA to a Luminex xMAP Assay using a Multiplex Antibody Screening Method
14:48

Conversion of a Capture ELISA to a Luminex xMAP Assay using a Multiplex Antibody Screening Method

Published on: July 6, 2012

45.4K

The TSH upper reference limit: where are we at?

Peter Laurberg1, Stig Andersen, Allan Carlé

  • 1Department of Endocrinology, Aalborg Hospital, Aarhus University Hospital, Postbox 365, DK-9100 Aalborg, Denmark. peter.laurberg@rn.dk

Nature Reviews. Endocrinology
|February 9, 2011
PubMed
Summary
This summary is machine-generated.

The upper limit for thyroid-stimulating hormone (TSH) reference intervals is debated. Current evidence suggests individualized TSH ranges may improve subclinical hypothyroidism diagnosis and treatment.

More Related Videos

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

2.8K
High-Resolution Ultrasonography for the Analysis of Orthotopic ATC Tumors in a Genetically Engineered Mouse Model
03:41

High-Resolution Ultrasonography for the Analysis of Orthotopic ATC Tumors in a Genetically Engineered Mouse Model

Published on: October 11, 2022

1.8K

Related Experiment Videos

Last Updated: Apr 30, 2026

Conversion of a Capture ELISA to a Luminex xMAP Assay using a Multiplex Antibody Screening Method
14:48

Conversion of a Capture ELISA to a Luminex xMAP Assay using a Multiplex Antibody Screening Method

Published on: July 6, 2012

45.4K
Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

2.8K
High-Resolution Ultrasonography for the Analysis of Orthotopic ATC Tumors in a Genetically Engineered Mouse Model
03:41

High-Resolution Ultrasonography for the Analysis of Orthotopic ATC Tumors in a Genetically Engineered Mouse Model

Published on: October 11, 2022

1.8K

Area of Science:

  • Endocrinology
  • Clinical Chemistry

Background:

  • Subclinical hypothyroidism diagnosis relies on serum TSH and T4 levels.
  • The upper limit of the TSH reference interval is critical for diagnosis.

Purpose of the Study:

  • To review the controversy surrounding TSH reference intervals.
  • To discuss the impact of age, race, sex, and iodine intake on TSH levels.
  • To evaluate evidence for adjusting the TSH upper reference limit.

Main Methods:

  • Review of population studies and clinical evidence.
  • Analysis of interindividual and intraindividual TSH variability.
  • Discussion of factors influencing TSH reference ranges.

Main Results:

  • Population data do not support lowering the TSH upper limit to 2.5 mU/l.
  • Current upper limits may be too low for certain demographics (elderly, women, white individuals).
  • Aging may increase TSH, but overt hypothyroidism can show a blunted TSH response in the elderly.

Conclusions:

  • TSH reference ranges require careful consideration of individual factors.
  • Lowering the TSH upper limit may lead to overdiagnosis and overtreatment.
  • Individualized levothyroxine treatment is essential for patients with elevated TSH.